Physician profile
Pranil Chandra
NPI 1093955338
$141,023.51
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $17K · 2021: $25K · 2022: $23K · 2023: $17K · 2024: $18K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $19K · Travel and Lodging: $3,640 · Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,419.50 |
| Consulting Fee | $18,802.68 |
| Travel and Lodging | $3,639.80 |
| Food and Beverage | $679.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45,136.57 | 2020-2025 | Enhertu, Lynparza, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $29,952.64 | 2019-2024 | |
| Abbvie INC. | $12,950.00 | 2022-2024 | |
| Amgen INC. | $10,702.79 | 2020-2025 | |
| Lilly USA, LLC | $9,781.87 | 2021-2025 | Retevmo |
| Emd Serono, INC. | $7,700.00 | 2020-2021 | |
| Roche Diagnostics Corporation | $6,792.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $5,640.17 | 2020-2023 | Keytruda |
| Janssen Biotech, INC. | $2,550.00 | 2022-2023 | Rybrevant |
| Ventana Medical Systems, INC. | $2,125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,875.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $1,860.00 | 2024 | |
| Stemline Therapeutics INC. | $1,800.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $1,039.04 | 2021 | |
| Blueprint Medicines Corporation | $823.45 | 2022-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $153.29 | 2024-2025 | Xt Cdx |
| Genentech, INC. | $61.51 | 2022-2025 | Alecensa |
| Eli Lilly and Company | $55.24 | 2019 | |
| Eusa Pharma (US) LLC | $24.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranil Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.